HLA-A and post-transplant lymphoproliferative disease: The relevance and clinical applicability of the highly immunodominant peptides A*03_BILF2VTLA, A*03_BcRF1FLLA and A*03_BALF3QVAT for PTLD and EBV-associated diseases were verified in HLA-A*03:01+ patients with EBV-associated PTLD after SOT.